Skip to main content

Table 4 Proportion of Clinical Response in both groups

From: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

  P013 (N = 107) Reference pertuzumab (N = 107)
Complete Response 64 (59.81) 61 (57.01)
Partial Response 30 (28.04) 29 (27.10)
Progressive Disease 2 (1.87) 3 (2.80)
Stable Disease 3 (2.80) 2 (1.87)
Unknown 8 (7.48) 12 (11.21)
  1. P-value = 0.99 (Fisher’s Exact test)
  2. Data are presented as No. (%)